Intellectual Product
FDAs policy, communications staff likely to be among agencys 3,500 staff cuts
Policy, Communication, Staff, United States Food and Drug Administration, CHARGE Syndrome
Eisai Revises Leqembi Sales Forecast for 2027, Remains Optimistic About Growth
Leqembi, Alzheimer’s disease, sales forecast, Eisai, Biogen, revenue projection
Trump’s Looming Pharmaceutical Tariffs: Uncertainty and Potential Impact
Trump, pharmaceutical tariffs, trade policy, drug prices, manufacturing, supply chain
DOGE Reverses Course on FDA Facility Closures, Including Major St. Louis Quality Lab
DOGE, FDA, lease terminations, St. Louis, drug quality lab, cost-cutting, reversal
A closer look at pharmas top patent losses in 2025
Legal patent, Expiration, function, Market, Indication of (contextual qualifier), competition, Impact food supplement, Sales – occupational activity, Bayer, 2025, patent cliff, Regeneron, 2023
Drugmakers renew concerns over UK’s attractiveness for investment
Investments, UK, UK ‘s, concerns, Industry, attractiveness
Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes
Continuous Glucose Monitoring System, Technology, Health Personnel, CGM, Diabetes Mellitus, Non-Insulin-Dependent
Trump Administration Considers Cuts to CDC’s HIV Prevention Program, Raising Concerns
HIV prevention, CDC funding cuts, Trump administration, public health, HIV/AIDS advocacy
AstraZeneca Inks $1.35B Deal with Alteogen for Subcutaneous Cancer Drugs Amid Industry Patent Disputes
AstraZeneca, Alteogen, subcutaneous cancer drugs, licensing agreement, patent dispute, Merck, Halozyme, hyaluronidase enzyme
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash